Embecta Q3 revenue $291.1M, net income $62.4M; raises H2 FY2022 margin guidance

Embecta Corp.

2022-Q3 EPS reported $4.14 revenue$854,900,000

Revenue $291.1M (-1.3% reported, +2.0% constant currency); US +4.1%, international -7.1%.
Net income $62.4M ($1.07 diluted EPS) vs $104.7M prior year; adjusted EBITDA margin 40.5% vs 48.7%.
Declared $0.15/share quarterly dividend, payable Sept. 14 to holders of record Aug. 26.
Raised H2 FY2022 adjusted gross margin guidance to mid-60%s (from low-60%s) and adjusted EBITDA margin to mid-30%s (from low-30%s); maintained revenue ~$555M.
Developing type 2 closed-loop insulin patch pump with FDA Breakthrough Device Designation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.